Objective: to conduct a cost-effectiveness analysis for estimation of the cost of an ongoing pregnancy in IVF/ICSI cycles comparing recombinant FSH vs human menopausal gonadotropins Methods: based on results of a recent published meta-analysis by our group, a Markov model was developed to conduct a cost-effectiveness analysis for estimation of the cost of an ongoing pregnancy in IVF/ICSI cycles. In addition, Monte Carlo micro-simulation was used to examine the potential impact of assumptions and other uncertainties represented in the model.
Introduction
The numbers of couples requiring advanced fertility treatment is increasing and hence, economic evaluation of different therapeutic interventions is important as the demand for services increases (1) . This is especially important if we put into consideration that despite, remarkable advances in infertility understanding and its management, success is limited and multiple treatment cycles may be needed to achieve a successful pregnancy.
Ovarian stimulation represents an excellent example. Multifollicular development via gonadotrophin administration is still an integral component for ovarian stimulation in IVF/ ICSI cycles. In the market, there are two major players: recombinant follicle stimulating hormone (recFSH) and human menopausal gonadotropin (hMG). Both effectiveness and costs should be considered together to aid the judgment about whether one drug should be preferred to a comparator (2) .
Despite of its proven efficacy, the relatively high cost of recFSH as compared to hMG has its impact on consumption (3) especially in developing countries (4) where its price (150 Egyptian pounds for 75 IU recFSH) is almost 3 times that of hMG (50 Egyptian pounds for 75 IU). In developing countries, although the cost of one trial of IVF is much lower than that in Europe, yet the majority of people cannot afford this treatment because of the low per capita income (5) . Even if they can afford one IVF cycle, it is documented that women in who do not pursue a second IVF cycle after the first fails, the major reason was financial (6)In a recently published meta-analysis by our group, it was demonstrated that there is no significant difference between hMG & recFSH regarding different IVF outcomes (7) with special concern to the most important outcome: Live Birth/ Ongoing Pregnancy rate Figure 1 ) were based on pooled outcome data that were collected from our recently published meta-analysis (7) ( Table 1 ).
The meta-analysis included eight truly RCTs (8) (9) (10) (11) (12) (13) (14) (15) Drug costs for recFSH and hMG were based on the most recent wholesale acquisition costs for the two agents in Egypt obtained from the Egyptian Ministry of Health (i.e. retail cost). Although these are the official prices, it should be noted that there is a variation in these prices between centers (i.e. actual price). All other costs corresponding to the relevant health states were taken (Table 2) varied by cycle number. Probability of discontinuation at the end of the cycle (failed clinical pregnancy) was obtained from another recent study as it was not possible to obtain it from meta-analysis (16) . The probability of discontinuation after the I s ' cycle is 0.489, after the second cycle would reach 0.524 and after the 3 rd cycle is 0.571 (16) . Patients ending with miscarriage were re-entered into the cycle. Probabilities were, again, drawn from the metaanalysis (7).
The OHSS complication is independent of IVF outcome. Hence, the cost incurred for OHSS management was placed early in the cycle to accumulate them regardless of where the cycle may end (i.e. ongoing pregnancy, re-start, or stopping 1VF). Patients, who cancelled early in the cycle for failed stimulation, were re-entered into the "start cycle" state, reincurring the costs of ovarian stimulation.
It was decided to run a Markov model for three cycles as many patients pursue a live birth through infertility treatment over a long treatment course, sometimes up to 10 or more cycles of treatment, however, financial and other personal costs often limit most patients to only 3 cycles of treatment. Then, to perform the analysis, a virtual population of 100,000
patients (the 'Markov cohort') was 'treated' in the computer simulation of ART treatment in Monte Carlo simulations. These large numbers of patients and simulations provided a high degree of statistical accuracy and allowed confidence limits around the outcome estimates to be generated with precision.
Results
Running the Markov model through three treatment cycles for recFSH resulted in the individual's probability of ending at re-starting the cycle is 6.6%, an ongoing pregnancy is 35.9%, and in discontinuing IVF is 57.5 % (Figure 2) . While for hMG, by the end of the 3rd cycle, the individual's probability of ending at re-starting the cycle is 6%, in ongoing pregnancy is 40.8%, and in discontinuing IVF is 53.2 % (Figure 3) . The hMG cycle costs on average EGP 13,946 per ongoing pregnancy, versus an average of EGP 18,721 per pregnancy, and a final 36% chance for recFSH (Table 4) . On performing sensitivity analysis on cost of hMG versus recFSH, it was found that the recFSH price should be 0.61 EGP/IU to be as cost effective as hMG at the price of 0.64 EGP/IU (i.e. around 60% reduction in its current price).
The total cost of 100,000 cycles in the hMG arm equals 1,392,633,925.40 (one billion and three hundred and ninety two million and six hundred and thirty three thousands). As it can be seen, the hMG arm exerts "absolute dominance" over the recFSH arm ( figure 2 -3 ). Further analyses, such as Incremental Cost Effectiveness, Threshold Analysis, etc., were therefore not possible.
One may argue that if there is no significant difference between both drugs and one is cheaper than the other, then it would be logic that hMG is more cost effective and no need for such a complex analysis. However, IVF/ ICSI cycles involve numerous steps. Each has its outcome probabilities and associated uncertainties. Therefore, it cannot simply be judged that the least costly treatment is the most effective or vice versa. Uncertainty plays a major role here. Moreover, it is important to know precisely how big the difference between the two drugs is.
Some may also argue that the meta-analysis from which the transition probabilities were drawn, found no statistically significant difference between hMG versus recFSH. We opted to repeat the calculations assuming identical effectiveness of both treatments of 25% of ongoing life birth rate, and re-examine their cost-effectiveness (Table 3) . The results were in the same direction, although the difference was less. From the calculation shown in Figure   4 , price of recombinant FSH should be reduced more than 50% to be equivalent to hMG in its cost effectiveness
In Egypt, only around 50 % of the Egyptian infertile couples could afford to pay for IVF (22) . We doubt that Egypt as a developing country, which has some private health care structures in place to offer tertiary level infertility care, stands alone in this matter. It was shown that in many developing countries around 10 per cent of all women's visits to doctors (all categories of medical doctors) are related to problems of childlessness. (23) Whereas the real cost for each live test-tube birth in the US is estimated at about $50,000, in a developing country setting, that cost could reach as high as $100,000 (24) . If IVF services are provided entirely by the private sector, then new reproductive technologies will benefit only a small proportion of infertile women, primarily elites, who can afford the costs associated with this technology (Inhorn et al., 1991) In conclusion, from an economic evaluation point of view, hMG was more costeffective than recFSH. The decision to adopt a more expensive treatment could result in a lower number of cycles of IVF/ICSI treatment especially if patients are paying for it. 
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